http://orcid.org/0000-0002-1879-1248
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
"Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency." Amyloid, 26(4), pp. 255–256
Disclosure statement
The authors report no conflicts of interest.
Additional information
Funding
The authors thank the patients and their families. Institutional research funding was provided by the National Natural Science Foundation of China [Grant No. 81570195, for LJ], Beijing Natural Science Foundation [Grant No. 7182128, for LJ], Foundation for Distinguished Young Physician of Peking Union Medical College Hospital [Grant No. JQ201501, for LJ], the CAMS Innovation Fund for Medical Sciences [Grant No. 2016-12M-1–002, for LJ], and The National Key Research and Development Program of China [Grant No. 2016YFC0901503, for LJ], the Capital Health Research and Development of Special Fund [Grant No.2018–2-4015], and the Fundamental Research Funds for the Central Universities, the Young Scientific Research Fund of PUMC [Grant No. 2017320004, for CX].